H
Heather L. McFarland
Researcher at AstraZeneca
Publications - 3
Citations - 509
Heather L. McFarland is an academic researcher from AstraZeneca. The author has contributed to research in topics: EGFR inhibitors & T790M. The author has an hindex of 3, co-authored 3 publications receiving 405 citations.
Papers
More filters
Journal ArticleDOI
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor
M. Raymond V. Finlay,Mark J. Anderton,Susan Ashton,Peter Ballard,Paul A. Bethel,Matthew R. Box,Robert Hugh Bradbury,Simon J. Brown,Sam Butterworth,Andrew D. Campbell,Christopher G. Chorley,Nicola Colclough,Darren Cross,Gordon S. Currie,Matthew Grist,Lorraine A. Hassall,George B. Hill,Daniel S. James,Michael James,Paul D. Kemmitt,Teresa Klinowska,Gillian M. Lamont,Scott G. Lamont,Nathaniel G. Martin,Heather L. McFarland,Martine J. Mellor,Jonathon P. Orme,David Perkins,Paula Perkins,Graham Richmond,Peter D. Smith,Richard A. Ward,Michael J. Waring,David Whittaker,Stuart L. Wells,Gail L. Wrigley +35 more
TL;DR: Following observations of significant tumor inhibition in preclinical models, the clinical candidate AZD9291 was administered clinically to patients with T790M positive EGFR-TKI resistant NSCLC and early efficacy has been observed, accompanied by an encouraging safety profile.
Journal ArticleDOI
Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer
Robert Hugh Bradbury,David G. Acton,Nicola Broadbent,A. Nigel Brooks,Carr Gregory Richard,Glenn Hatter,Barry R. Hayter,Hill Kathryn Jane,Nicholas J. Howe,Rhys D.O. Jones,David A. Jude,Scott G. Lamont,Sarah A. Loddick,Heather L. McFarland,Zaieda Parveen,Alfred A. Rabow,Gorkhn Sharma-Singh,Natalie Stratton,Andrew G. Thomason,Dawn Trueman,Graeme Walker,Stuart L. Wells,Joanne Wilson,J. Matthew Wood +23 more
TL;DR: Clinical candidate 6-(4-{4-[2-acetylpiperazin-1-yl)-3-(trifluoromethyl)-7,8-dihydro[1,2,4]triazolo[4,3-b]pyridazine (12), designated AZD3514, that is being evaluated in a Phase I clinical trial in patients with castrate-resistant prostate cancer.
Proceedings ArticleDOI
Abstract B94: Discovery of and first disclosure of the clinical candidate AZD9291, a potent and selective third-generation EGFR inhibitor of both activating and T790M resistant mutations that spares the wild type form of the receptor.
M. Raymond V. Finlay,Mark J. Anderton,Susan Ashton,Peter Ballard,Rob H. Bradbury,Sam Butterworth,Claudio Chuaqui,Nicola Colclough,Darren Cross,Heather L. McFarland,Martine J. Mellor,Richard A. Ward,Michael J. Waring +12 more
TL;DR: The discovery of and first disclosure of the clinical candidate AZD9291, a potent and selective third-generation EGFR inhibitor of both activating and T790M resistant mutations that spares the wild type form of the receptor.